Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B: “Treat all” or “Treat select”

  • Point-of-View
  • Published:
Hepatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

CHB:

Chronic hepatitis B

HCC:

Hepatocellular carcinoma

WHO:

World Health Organization

IDAHS:

Incidentally detected asymptomatic HBsAg-positive subjects

IA:

Immune active

IT:

Immune tolerant

MTCT:

Mother-to-child transmission

NVHCP:

National Viral Hepatitis Control Program

TDF:

Tenofovir disoproxil fumarate

TAF:

Tenofovir alafenamide

ETV:

Entecavir

References

  1. World Health Organization. Hepatitis B. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed Sep 4, 2022.

  2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-1273.e1

    Article  Google Scholar 

  3. Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. Liver Int. 2018;38(suppl 1):122–125

    Article  Google Scholar 

  4. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98

    Article  CAS  Google Scholar 

  5. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283

    Article  Google Scholar 

  6. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398

    Article  Google Scholar 

  7. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J Am Med Assoc. 2006;295:65–73

    Article  CAS  Google Scholar 

  8. Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67:945–952

    Article  CAS  Google Scholar 

  9. Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int. 2008;2(2):179–184

    Article  Google Scholar 

  10. Chan HLY, Chan CK, Hui AJ, Chan S, Poordad F, Chang T-T, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240–1248

    Article  CAS  Google Scholar 

  11. Duan M, Chi X, Xiao H, Liu X, Zhuang H. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int. 2021;15:318–327

    Article  Google Scholar 

  12. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol. 2009;104:1693–1699

    Article  Google Scholar 

  13. Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the “inactive carrier” phase. Hepatol Int. 2021;15:290–300

    Article  Google Scholar 

  14. Ford N, Scourse R, Lemoine M, Hutin Y, Bulterys M, Shubber Z, et al. Adherence to Nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2(10):1160–1167

    Article  Google Scholar 

  15. Su, et al. Withdrawal of nucleos(t)ide analogues in hepatitis B e antigen-negative patients: an Asian perspective. Clin Liver Dis (Hoboken). 2021;16(6):244–248

    Article  Google Scholar 

  16. Kao, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833–851

    Article  Google Scholar 

  17. Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425–434

    Article  CAS  Google Scholar 

  18. Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood). 2011;30:340–348

    Article  Google Scholar 

  19. Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080—gaps, challenges and targets. Indian J Med Res. 2014;140(1):1–4

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Hepatology, Institute of Liver and Biliary Sciences, D – 1, Vasant Kunj, New Delhi, 110070, India

    Ankur Jindal & Shiv K. Sarin

Authors
  1. Ankur Jindal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiv K. Sarin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AJ—writing of manuscript; SKS—critical revision.

Corresponding author

Correspondence to Ankur Jindal.

Ethics declarations

Conflict of interest

The authors Ankur Jindal and Shiv K. Sarin have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jindal, A., Sarin, S.K. Hepatitis B: “Treat all” or “Treat select”. Hepatol Int 17, 38–41 (2023). https://doi.org/10.1007/s12072-022-10441-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-022-10441-5

Keywords

Search

Navigation